Carterra

Carterra is a private, revenue-generating company providing a platform technology for high-throughput biophysical analysis in drug discovery. Founded in 2014 and headquartered in Salt Lake City, Utah, the company's core innovation is a microfluidic SPR imaging system that allows for the parallel screening of thousands of antibody-antigen interactions daily, using minimal sample. This platform is critical for applications like epitope binning, kinetics analysis, and early-stage characterization, serving major pharmaceutical firms and biotechs. Carterra's technology is positioned as an enabling tool for advancing AI/ML in biologics discovery and improving R&D efficiency.

Patented microfluidic technology integrated with Surface Plasmon Resonance imaging (SPRi) for massively parallel, high-throughput screening and characterization of biomolecular interactions. The platform uses disposable cartridges to analyze up to 384 interactions simultaneously on a single sensor chip, with minimal sample consumption.

Carterra competes in the biophysical characterization and high-throughput screening market. Direct competitors include other SPR instrument manufacturers (e.g., Cytiva, Bruker, Nicoya), as well as providers of Bio-Layer Interferometry (BLI) systems (e.g., Sartorius). Carterra's key differentiator is its massively parallel, array-based SPR imaging capability, which offers superior throughput for epitope binning and kinetics compared to traditional serial SPR systems.